Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
O413808-2mg | 2mg | In stock | $51.90 | |
O413808-5mg | 5mg | In stock | $107.90 | |
O413808-10mg | 10mg | In stock | $147.90 | |
O413808-25mg | 25mg | In stock | $333.90 | |
O413808-50mg | 50mg | In stock | $444.90 | |
O413808-100mg | 100mg | In stock | $642.90 |
Nrf2 Activators
Synonyms | DTXSID101138251 | GTPL7573 | MFCD28167769 | N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoropropanamide | omaveloxolona | AKOS037648676 | N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a, |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Biochemical and Physiological Mechanisms | Omaveloxolone (RTA-408) is a synthetic triterpenoid that activates the cytoprotective transcription factor Nrf2 and inhibits NF-κB signaling. Phase 2. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | ACTIVATOR |
Mechanism of action | Activator of nuclear factor; erythroid 2 like 2 |
Product Description | Information Omaveloxolone (RTA-408) Omaveloxolone (RTA-408) is a synthetic triterpenoid that activates the cytoprotective transcription factor Nrf2 and inhibits NF-κB signaling. Phase 2. Targets NF-κB ; Nrf2 In vitro RTA 408 potently increases expression of Nrf2 target genes and reverses IFNγ-mediated suppression of Gclc expression in RAW 264.7 cells. In a panel of eight human tumor cell lines, RTA 408 inhibits growth with an average GI50 value of 260 nM and induces apoptosis. RTA 408 also inhibits NF-κB and activates JNK in tumor cells. In vivo In mice with radiation-induced dermatitis, 1.0% RTA 408 markedly reduces epidermal and collagen thickening, prevents dermal necrosis and completely alleviates skin ulcers. In rat skin, RTA 408 activates Nrf2 and induces cytoprotective genes. RTA 408 also mitigates hematopoietic acute radiation syndrome in mice. Cell Research(from reference) Cell lines:A375, NCI-H460, A2058, MDA-Mb-231, HCT116, 786-0, A549, and PANC-1 cells Concentrations:~1 μM Incubation Time:72 hours |
ALogP | 5.339 |
---|---|
HBD Count | 1 |
Rotatable Bond | 2 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Pubchem Sid | 488202305 |
---|---|
Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/488202305 |
IUPAC Name | N-[(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicen-4a-yl]-2,2-difluoropropanamide |
INCHI | InChI=1S/C33H44F2N2O3/c1-27(2)11-13-33(37-26(40)32(8,34)35)14-12-31(7)24(20(33)17-27)21(38)15-23-29(5)16-19(18-36)25(39)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3,(H,37,40)/t20-,22-,24-,29-,30+,31+,33-/m0/s1 |
InChi Key | RJCWBNBKOKFWNY-IDPLTSGASA-N |
Canonical SMILES | CC1(CCC2(CCC3(C(C2C1)C(=O)C=C4C3(CCC5C4(C=C(C(=O)C5(C)C)C#N)C)C)C)NC(=O)C(C)(F)F)C |
Isomeric SMILES | C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)NC(=O)C(C)(F)F |
Alternate CAS | 1474034-05-3 |
PubChem CID | 71811910 |
MeSH Entry Terms | N-(11-cyano-2,2,6a,6b,9,9,12a-heptmethyl-10,14-dioxo-1,3,4,5,6a,6b,7,8,8a,9,10,12a,14,14a,14b-hexadecahydro-2H-picen-4a-yl)-2-2-difluoropropionamide;Omaveloxolone;RTA 408;RTA-408 |
Molecular Weight | 554.71 |
PubChem SID | 488202305 |
---|
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
B2327605 | Certificate of Analysis | Aug 25, 2022 | O413808 |
B2327608 | Certificate of Analysis | Aug 25, 2022 | O413808 |
B2327612 | Certificate of Analysis | Aug 25, 2022 | O413808 |
B2327613 | Certificate of Analysis | Aug 25, 2022 | O413808 |
B2327617 | Certificate of Analysis | Aug 25, 2022 | O413808 |
B2327642 | Certificate of Analysis | Aug 25, 2022 | O413808 |
B2327644 | Certificate of Analysis | Aug 25, 2022 | O413808 |
B2327645 | Certificate of Analysis | Aug 25, 2022 | O413808 |
B2327646 | Certificate of Analysis | Aug 25, 2022 | O413808 |
B2327647 | Certificate of Analysis | Aug 25, 2022 | O413808 |
B2327648 | Certificate of Analysis | Aug 25, 2022 | O413808 |
B2327669 | Certificate of Analysis | Aug 25, 2022 | O413808 |
Solubility | Solubility (25°C) In vitro DMSO: 100 mg/mL (180.27 mM); Ethanol: 3 mg/mL (5.4 mM); Water: Insoluble; |
---|---|
DMSO(mg / mL) Max Solubility | 100 |
DMSO(mM) Max Solubility | 180.2743776 |
Water(mg / mL) Max Solubility | <1 |
1. Reisman SA, Lee CY, Meyer CJ, Proksch JW, Ward KW. (2014) Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin.. Arch Dermatol Res, 306 (5): (447-54). [PMID:24362512] [10.1021/op500134e] |
2. Reisman SA, Lee CY, Meyer CJ, Proksch JW, Sonis ST, Ward KW. (2014) Topical application of the synthetic triterpenoid RTA 408 protects mice from radiation-induced dermatitis.. Radiat Res, 181 (5): (512-20). [PMID:24720753] [10.1021/op500134e] |
3. Reisman SA, Gahir SS, Lee CI, Proksch JW, Sakamoto M, Ward KW. (2019) Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates.. Drug Des Devel Ther, 13 (13): (1259-1270). [PMID:31118567] [10.1021/op500134e] |
4. Ghanekar SD, Miller WW, Meyer CJ, Fenelon KJ, Lacdao A, Zesiewicz TA. (2019) Orphan Drugs In Development For The Treatment Of Friedreich's Ataxia: Focus On Omaveloxolone.. Degener Neurol Neuromuscul Dis, 9 (13): (103-107). [PMID:31686946] [10.1021/op500134e] |
5. Profeta V, McIntyre K, Wells M, Park C, Lynch DR. (2023) Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia.. Expert Opin Investig Drugs, 32 (1): (5-16). [PMID:36708320] [10.1021/op500134e] |